Description
: PMEC 1% Cream, manufactured by Navana Pharmaceuticals Ltd., contains 1% pimecrolimus as its active ingredient. It is a topical immunosuppressant used for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (eczema) in non-immunocompromised adults and children aged 2 years and older who have failed to respond adequately to other topical prescription treatments or when those treatments are not advisable. PMEC works by inhibiting the activation of T-cells and preventing the release of inflammatory mediators from mast cells, thereby reducing inflammation and symptoms associated with eczema. The cream should be applied as a thin layer to the affected areas twice daily. Treatment should be discontinued if there is no improvement after 6 weeks or if the condition worsens. PMEC is contraindicated in individuals with known hypersensitivity to pimecrolimus or any component of the cream, and its safety and efficacy have not been established in children under 2 years of age. Common side effects may include a burning sensation at the application site, headache, and upper respiratory tract infections
Change Language